Citations

Mayo Clinic

Showing 10 of 108599 citations.

U.S. Diagnostic Reference Levels and Achievable Doses for 10 Adult CT Examinations
Kanal, Kalpana M. , Butler, Priscilla F. , Sengupta, Debapriya , Bhargavan, Mythreyi , Coombs, Laura P. , Morin, Richard L. , Bhargavan-Chatfield, Mythreyi

Radiology | February 21, 2017 | Volume: 284 | Issue: 1 | Pages: 120-133

10.1148/radiol.2017161911 | PMID 28221093 Get It

Characteristics and Outcomes of Fasting Orders Among Medical Inpatients
Sorita, Atsushi , Ratelle, John T. , Bates, Ruth , Rieck, Katie M. , Devalapalli, Aditya P., Ahmed, Adil , Kashiwagi, Deanne T. , Bates, Ruth E, Thongprayoon, Charat

Journal of Hospital Medicine | February 21, 2017 | Volume: 12 | Issue: 1 | Pages: 36-39

10.1002/jhm.2674 | PMID 28125828 Get It

While many hospitalized patients have orders to fast in preparation for interventions, the extent to which these orders are necessary or adhere to evidence‐based durations is unknown. In this study, we analyzed the length, indication, and associated outcomes of nil per os (NPO) orders for general medicine patients at an academic institution in the United States, and compared them to the best available evidence for recommended length of NPO. Of 924 NPO orders assessed, the indicated intervention was not performed for 183 (19.8%) orders, largely due to a change in plan (75/183, 41.0%) or scheduling barriers (43/183, 23.5%). When analyzed by indication, the median duration of NPO orders ranged from 8.3 hours for kidney ultrasound to 13.9 hours for upper endoscopy. For some indications, the literature suggested NPO orders may be unnecessary. Furthermore, in indications for which NPO was deemed necessary in the literature, the duration of most NPO orders was much longer than minimally required. These results suggest the need for establishing more robust practice guidelines or institutional protocols for NPO orders.
Clinical Conundrum of Coronary Artery Disease and Aortic Valve Stenosis
Sabbagh, Abdallah El , El Sabbagh, Abdallah, Nishimura, Rick A.

Journal of the American Heart Association | February 21, 2017 | Volume: 6 | Issue: 2 | Pages: No page available

10.1161/jaha.117.005593 | PMID 28219922 Get It

Primary Hepatic Neuroendocrine Tumor with Unusual Thyroid Follicular-Like Morphologic Characteristics
Ibrahim, Mohd Elmugtaba , Abadeer, Kerolos, Zhai, Qihui, Nassar, Aziza , Zhai, Qihui Jim, Nassar, Aziza

Case Reports in Pathology | February 20, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-6

10.1155/2017/7931975 | PMID 28316853 Get It

We describe a primary hepatic neuroendocrine tumor of a 57-year-old Thai woman who presented in 2004 with a suspicious mass in the left hepatic lobe. She underwent left hepatectomy for the 10.5-cm mass, calledintermediate grade neuroendocrine carcinoma of unknown origin,likely metastatic. The tumor recurred in 2007, then calledrecurrent primary hepatic neuroendocrine tumor(PHNET), and the patient underwent liver transplant. Because of similarity between the neuroendocrine tumor and a thyroid tumor—specifically, follicular-like characteristics—immunohistochemical stains for thyroglobulin, TTF1, and calcitonin were performed. However, all were negative. All imaging studies revealed no evidence of a primary lesion other than the liver mass. In 2008, the patient’s liver transplant failed because of ischemic cholangiopathy, and she underwent a second liver transplant. Seven years later, in 2015, she presented with metastatic neuroendocrine tumor of intermediate grade to the lung, consistent with metastatic PHNET. She underwent left upper-lobe wedge resection to remove the tumor. The patient is alive with no evidence of disease at 13 years after initial diagnosis. This rare variant of PHNET had thyroid-like morphologic characteristics but there is no evidence of primary thyroid tumor or thyroid markers in the primary and recurrent hepatic tumors and lung metastasis.
Pharmacokinetics and Pharmacodynamics of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: Phase 2 Trials for Dose Selection in the Pivotal Phase 3 Trial
Shoaf, Susan E. , Chapman, Arlene B., Torres, Vicente E. , Ouyang, John , Czerwiec, Frank S., Torres, Vicente E

The Journal of Clinical Pharmacology | February 20, 2017 | Volume: 57 | Issue: 7 | Pages: 906-917

10.1002/jcph.880 | PMID 28218410 Get It

Transgene Expression and Host Cell Responses to Replication-Defective, Single-Cycle, and Replication-Competent Adenovirus Vectors
Crosby, Catherine M. , Barry, Michael A. , Barry, Michael A

Genes | February 20, 2017 | Volume: 8 | Issue: 2 | Pages: 79

10.3390/genes8020079 | PMID 28218713 Get It

Most adenovirus (Ad) vectors are E1 gene deleted replication defective (RD-Ad) vectors that deliver one transgene to the cell and all expression is based on that one gene. In contrast, E1-intact replication-competent Ad (RC-Ad) vectors replicate their DNA and their transgenes up to 10,000-fold, amplifying transgene expression markedly higher than RD-Ad vectors. While RC-Ad are more potent, they run the real risk of causing adenovirus infections in vector recipients and those that administer them. To gain the benefits of transgene amplification, but avoid the risk of Ad infections, we developed “single cycle” Ad (SC-Ad) vectors. SC-Ads amplify transgene expression and generated markedly stronger and more persistent immune responses than RD-Ad as expected. However, they also unexpectedly generated stronger immune responses than RC-Ad vectors. To explore the basis of this potency here, we compared gene expression and the cellular responses to infection to these vectors in vitro and in vivo. In vitro, in primary human lung epithelial cells, SC- and RC-Ad amplified their genomes more than 400-fold relative to RD-Ad with higher replication by SC-Ad. This replication translated into higher green fluorescent protein (GFP) expression for 48 h by SC- and RC-Ad than by RD-Ad. In vitro, in the absence of an immune system, RD-Ad expression became higher by 72 h coincident with cell death mediated by SC- and RC-Ad and release of transgene product from the dying cells. When the vectors were compared in human THP-1 Lucia- interferon-stimulated gene (ISG) cells, which are a human monocyte cell line that have been modified to quantify ISG activity, RC-Ad6 provoked significantly stronger ISG responses than RD- or SC-Ad. In mice, intravenous or intranasal injection produced up to 100-fold genome replication. Under these in vivo conditions in the presence of the immune system, luciferase expression by RC and SC-Ad was markedly higher than that by RD-Ad. In immunodeficient mice, SC-Ad drove stronger luciferase expression than RC- or RD-Ad. These data demonstrate better transgene expression by SC- and RC-Ad in vitro and in vivo than RD-Ad. This higher expression by the replicating vectors results in a peak of expression within 1 to 2 days followed by cell death of infected cells and release of transgene products. While SC- and RC-Ad expression were similar in mice and in Syrian hamsters, RC-Ad provoked much stronger ISG induction which may explain in part SC-Ad′s ability to generate stronger and more persistent immune responses than RC-Ad in Ad permissive hamsters.
How Do We Treat Human Herpesvirus 6 Infection After Allogeneic Hematopoietic Stem Cell transplantation?
Aburjania, Nana , Saleh, Omar Abu , Razonable, Raymund R.

Future Virology | February 20, 2017 | Volume: 12 | Issue: 3 | Pages: 85-88

10.2217/fvl-2016-0140 Get It

Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability
Padmanabhan, Vijayalakshmi , Marshall, Carrie B. , Barkan, Güliz A. , Ghofrani, Mohiedean , Laser, Alice, Ocal, Idris Tolgay, Souers, Rhona J., Tolgay Ocal, Idris, Sturgis, Charles D. , Kurtycz, Daniel F. I.

Diagnostic Cytopathology | February 20, 2017 | Volume: 45 | Issue: 5 | Pages: 399-405

10.1002/dc.23681 | PMID 28217980 Get It

BackgroundThe Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) offers a six‐tiered diagnostic scheme for thyroid Fine Needle Aspiration (FNA): Benign, Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance (AUS/FLUS), suspicious for follicular neoplasm, suspicious for malignancy, malignant, and unsatisfactory with an aim to standardize diagnostic criteria. Reported rate of AUS/FLUS category in the literature has varied from 3% to 20.5%.MethodsThe aim of this study was to assess interobserver variability among cytopathologists to assess reproducibility of the AUS/FLUS category. Seven cytopathologists brought FNA cases (a mixture of atypical and non‐atypical FNA diagnosis) diagnosed using TBSRTC from their respective institutions which were reviewed and diagnosed by the participants. The analysis assessed interobserver variability among 7 cytopathologists and determined characteristics on the slides which were associated with concordance to the institutional diagnosis.ResultsSeventy eight of 125 (62.4%) benign cases were classified as benign by the reviewers and 26 (21%) were called AUS/FLUS on review. A third of the AUS/FLUS cases were called benign on review and 28.2% were classified as suspicious for neoplasia/malignancy. Roughly a third each of the suspicious for follicular neoplasm/suspicious for malignancy cases were classified as AUS/FLUS.DiscussionWhen pathologists from different institutions shared their slides, concordance was high for specimens with adequate cellularity and those that were clearly benign but thresholds varied for the other indeterminate categories. Most definite categorization of the AUS/FLUS category was seen on review. Diagn. Cytopathol. 2017;45:399–405. © 2017 Wiley Periodicals, Inc.
Reply
Maciel, Gabriel, Crowson, Cynthia S. , Matteson, Eric L. , Cornec, Divi, Cornec, Divi

Arthritis Care & Research | February 19, 2017 | Volume: 70 | Issue: 6 | Pages: 953-954

10.1002/acr.23222 | PMID 28217854 Get It

Soluble ST2 in Heart Failure With Preserved Ejection Fraction
AbouEzzeddine, Omar F. , Stevens, Susanna R., Felker, G. Michael , Borlaug, Barry A. , Chen, Horng H. , Redfield, Margaret M. , McKie, Paul M. , Dunlay, Shannon M. , Tracy, Russell P. , Braunwald, Eugene , Borlaug, Barry A , AbouEzzeddine, Omar F

Journal of the American Heart Association | February 19, 2017 | Volume: 6 | Issue: 2 | Pages: No page available

10.1161/jaha.116.004382 | PMID 28214792 Get It

Background Soluble ST2 is a biomarker that is elevated in certain systemic inflammatory diseases. Comorbidity‐driven microvascular inflammation is postulated to play a key role in heart failure with preserved ejection fraction ( HF p EF ) pathophysiology, but data on how sST 2 relates to clinical characteristics or inflammatory conditions or biomarkers in HF p EF are limited. We sought to determine circulating levels and clinical correlates of sST 2 in HF pEF. Methods and Results At enrollment, patients (n=174) from the Phosphodiesterase‐5 Inhibition to Improve Clinical Status And Exercise Capacity in Diastolic Heart Failure (RELAX) trial of sildenafil in HF p EF had sST 2 levels measured. Clinical characteristics; cardiac structure and function; exercise performance; and biomarkers of neurohumoral activation, systemic inflammation and fibrosis, and myocardial necrosis were assessed in relation to sST 2 levels. Median sST 2 levels in male and female HFpEF patients were 36.7 ng/mL (range 30.9–49.2 ng/mL; reference range 4–31 ng/mL) and 30.8 ng/mL (range 25.3–39.3 ng/mL; reference range 2–21 ng/mL), respectively. Among HF p EF patients, higher sST 2 levels were associated with the presence of diabetes mellitus; atrial fibrillation; renal dysfunction; right ventricular pressure overload and dysfunction; systemic congestion; exercise intolerance; and biomarkers of systemic inflammation and fibrosis, neurohumoral activation, and myocardial necrosis ( P <0.05 for all). sST 2 was not associated with left ventricular structure or left ventricular systolic or diastolic function. Conclusions In HF p EF , sST 2 levels were associated with proinflammatory comorbidities, right ventricular pressure overload and dysfunction, and systemic congestion but not with left ventricular geometry or function. These data suggest that sST2 may be a marker of systemic inflammation in HF p EF and potentially of extracardiac origin. Clinical Trial Registration URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00763867.